This company listing is no longer active
6998 Stock Overview
A biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genor Biopharma Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.51 |
| 52 Week High | HK$14.34 |
| 52 Week Low | HK$2.33 |
| Beta | 0 |
| 11 Month Change | -19.55% |
| 3 Month Change | -27.25% |
| 1 Year Change | -78.02% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6998 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -18.5% | -0.7% | -1.0% |
| 1Y | -78.0% | -34.6% | 0.7% |
Return vs Industry: 6998 underperformed the Hong Kong Biotechs industry which returned -15.9% over the past year.
Return vs Market: 6998 underperformed the Hong Kong Market which returned -14.1% over the past year.
Price Volatility
| 6998 volatility | |
|---|---|
| 6998 Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 6998's share price has been volatile over the past 3 months.
Volatility Over Time: 6998's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 452 | Feng Guo | www.genorbio.com |
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company’s principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn’s disease, and fistulising crohn’s disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials.
Genor Biopharma Holdings Limited Fundamentals Summary
| 6998 fundamental statistics | |
|---|---|
| Market cap | HK$1.26b |
| Earnings (TTM) | -HK$981.49m |
| Revenue (TTM) | HK$3.33m |
378.4x
P/S Ratio-1.3x
P/E RatioIs 6998 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6998 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.96m |
| Cost of Revenue | CN¥787.00k |
| Gross Profit | CN¥2.17m |
| Other Expenses | CN¥872.13m |
| Earnings | -CN¥869.96m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 73.38% |
| Net Profit Margin | -29,430.38% |
| Debt/Equity Ratio | 0% |
How did 6998 perform over the long term?
See historical performance and comparison